<DOC>
	<DOCNO>NCT03086239</DOCNO>
	<brief_summary>This Japanese , multicenter , open-label , dose-escalation study . This first study ass safety tolerability well explore pharmacokinetics , pharmacodynamics antitumor activity rovalpituzumab tesirine Japanese participant advance small cell lung cancer ( SCLC ) .</brief_summary>
	<brief_title>A Study Safety Tolerability Rovalpituzumab Tesirine Japanese Patients With Advanced , Recurrent Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Histologically cytologically confirm advanced , recurrent smallcell lung cancer ( SCLC ) document disease progression least two ( 2 ) prior systemic regimen , include least one ( 1 ) platinumbased regimen . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate hematologic , hepatic renal function . No prior exposure pyrrolobenzodiazepine ( PBD ) base drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced , Recurrent Small Cell Lung Cancer</keyword>
	<keyword>Rovalpituzumab tesirine</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Cancer</keyword>
</DOC>